Armistice Capital LLC grew its stake in Genprex, Inc. (NASDAQ:GNPX – Free Report) by 122.7% during the second quarter, HoldingsChannel reports. The fund owned 218,000 shares of the company’s stock after acquiring an additional 120,132 shares during the quarter. Armistice Capital LLC owned about 0.10% of Genprex worth $411,000 as of its most recent SEC filing.
Genprex Stock Performance
Shares of NASDAQ GNPX opened at $0.35 on Friday. Genprex, Inc. has a 1-year low of $0.28 and a 1-year high of $16.94. The business has a fifty day moving average price of $0.94 and a 200 day moving average price of $1.97.
Genprex (NASDAQ:GNPX – Get Free Report) last announced its earnings results on Friday, August 9th. The company reported ($3.00) EPS for the quarter, missing analysts’ consensus estimates of ($2.30) by ($0.70). On average, research analysts predict that Genprex, Inc. will post -5.7 EPS for the current year.
Genprex Profile
Genprex, Inc, a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes.
See Also
- Five stocks we like better than Genprex
- Profitably Trade Stocks at 52-Week Highs
- Rocket Lab Stock Soars: Should Investors Chase the Rally?
- Find and Profitably Trade Stocks at 52-Week Lows
- KB Home Slips After Earnings: What’s Next for Homebuilders?
- The Risks of Owning Bonds
- Micron Stock Soars as AI Demand Fuels Big Q4 Earnings Beat
Want to see what other hedge funds are holding GNPX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genprex, Inc. (NASDAQ:GNPX – Free Report).
Receive News & Ratings for Genprex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genprex and related companies with MarketBeat.com's FREE daily email newsletter.